Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2012 by Columbia University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Columbia University
ClinicalTrials.gov Identifier:
NCT00583349
First received: December 20, 2007
Last updated: November 2, 2012
Last verified: November 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)